These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18556779)

  • 1. Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload.
    Vinchi F; Gastaldi S; Silengo L; Altruda F; Tolosano E
    Am J Pathol; 2008 Jul; 173(1):289-99. PubMed ID: 18556779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases.
    Vinchi F; De Franceschi L; Ghigo A; Townes T; Cimino J; Silengo L; Hirsch E; Altruda F; Tolosano E
    Circulation; 2013 Mar; 127(12):1317-29. PubMed ID: 23446829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced splenomegaly and severe liver inflammation in haptoglobin/hemopexin double-null mice after acute hemolysis.
    Tolosano E; Fagoonee S; Hirsch E; Berger FG; Baumann H; Silengo L; Altruda F
    Blood; 2002 Dec; 100(12):4201-8. PubMed ID: 12393471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: Role of heme oxygenase-1 induction.
    Belcher JD; Chen C; Nguyen J; Abdulla F; Zhang P; Nguyen H; Nguyen P; Killeen T; Miescher SM; Brinkman N; Nath KA; Steer CJ; Vercellotti GM
    PLoS One; 2018; 13(4):e0196455. PubMed ID: 29694434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent roles of haptoglobin and hemopexin deficiency for disease progression of Shiga-toxin-induced hemolytic-uremic syndrome in mice.
    Pirschel W; Mestekemper AN; Wissuwa B; Krieg N; Kröller S; Daniel C; Gunzer F; Tolosano E; Bauer M; Amann K; Heinemann SH; Coldewey SM
    Kidney Int; 2022 Jun; 101(6):1171-1185. PubMed ID: 35031328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis.
    Merle NS; Grunenwald A; Figueres ML; Chauvet S; Daugan M; Knockaert S; Robe-Rybkine T; Noe R; May O; Frimat M; Brinkman N; Gentinetta T; Miescher S; Houillier P; Legros V; Gonnet F; Blanc-Brude OP; Rabant M; Daniel R; Dimitrov JD; Roumenina LT
    Front Immunol; 2018; 9():179. PubMed ID: 29545789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heme Oxygenase Activity and Heme Binding in a Neonatal Mouse Model.
    Kourula S; Ang J; Zhao H; Kalish F; Vandenabeele P; Sylvester KG; Wong RJ; Stevenson DK
    Neonatology; 2017; 112(4):376-383. PubMed ID: 28926834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation.
    Poillerat V; Gentinetta T; Leon J; Wassmer A; Edler M; Torset C; Luo D; Tuffin G; Roumenina LT
    Front Immunol; 2020; 11():1684. PubMed ID: 32849588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial cell heme oxygenase and ferritin induction by heme proteins: a possible mechanism limiting shock damage.
    Balla J; Jacob HS; Balla G; Nath K; Vercellotti GM
    Trans Assoc Am Physicians; 1992; 105():1-6. PubMed ID: 1308986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches to limit hemolysis-driven endothelial dysfunction: scavenging free heme to preserve vasculature homeostasis.
    Vinchi F; Tolosano E
    Oxid Med Cell Longev; 2013; 2013():396527. PubMed ID: 23781294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice.
    Tolosano E; Hirsch E; Patrucco E; Camaschella C; Navone R; Silengo L; Altruda F
    Blood; 1999 Dec; 94(11):3906-14. PubMed ID: 10572107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial dysfunction inhibits the ability of haptoglobin to prevent hemoglobin-induced hypertension.
    Graw JA; Yu B; Rezoagli E; Warren HS; Buys ES; Bloch DB; Zapol WM
    Am J Physiol Heart Circ Physiol; 2017 Jun; 312(6):H1120-H1127. PubMed ID: 28314763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.
    Merle NS; Grunenwald A; Rajaratnam H; Gnemmi V; Frimat M; Figueres ML; Knockaert S; Bouzekri S; Charue D; Noe R; Robe-Rybkine T; Le-Hoang M; Brinkman N; Gentinetta T; Edler M; Petrillo S; Tolosano E; Miescher S; Le Jeune S; Houillier P; Chauvet S; Rabant M; Dimitrov JD; Fremeaux-Bacchi V; Blanc-Brude OP; Roumenina LT
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of total and unbound cell-free heme in plasma of patients with sickle cell disease.
    Vissa M; Larkin SK; Vichinsky EP; Kuypers FA; Soupene E
    Exp Biol Med (Maywood); 2023 May; 248(10):897-907. PubMed ID: 36941786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity.
    Deuel JW; Vallelian F; Schaer CA; Puglia M; Buehler PW; Schaer DJ
    Free Radic Biol Med; 2015 Dec; 89():931-43. PubMed ID: 26475040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free heme exacerbates colonic injury induced by anti-cancer therapy.
    Seika P; Janikova M; Asokan S; Janovicova L; Csizmadia E; O'Connell M; Robson SC; Glickman J; Wegiel B
    Front Immunol; 2023; 14():1184105. PubMed ID: 37342339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and feasibility of the gene transfer of hemopexin for conditions with increased free heme.
    de Lima F; Hounkpe BW; de Moraes CRP; Borba-Junior IT; Costa FF; De Paula EV
    Exp Biol Med (Maywood); 2023 Jul; 248(13):1103-1111. PubMed ID: 37452705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intravascular hemolysis in malaria on liver dysfunction: involvement of hepatic free heme overload, NF-κB activation, and neutrophil infiltration.
    Dey S; Bindu S; Goyal M; Pal C; Alam A; Iqbal MS; Kumar R; Sarkar S; Bandyopadhyay U
    J Biol Chem; 2012 Aug; 287(32):26630-46. PubMed ID: 22696214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease.
    Vinchi F; Costa da Silva M; Ingoglia G; Petrillo S; Brinkman N; Zuercher A; Cerwenka A; Tolosano E; Muckenthaler MU
    Blood; 2016 Jan; 127(4):473-86. PubMed ID: 26675351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner.
    Merle NS; Paule R; Leon J; Daugan M; Robe-Rybkine T; Poillerat V; Torset C; Frémeaux-Bacchi V; Dimitrov JD; Roumenina LT
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6280-6285. PubMed ID: 30850533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.